Immunome, Inc. (IMNM)

$5.35

-0.02 (-0.37%)
Rating:
Recommendation:
-
Symbol IMNM
Price $5.35
Beta 0.833
Volume Avg. 0.08M
Market Cap 64.889M
Shares () -
52 Week Range 2.09-8.97
1y Target Est -
DCF Unlevered IMNM DCF ->
DCF Levered IMNM LDCF ->
ROE -106.05% Strong Sell
ROA -121.00% Strong Sell
Operating Margin -
Debt / Equity 32.33% Neutral
P/E -
P/B 2.81 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest IMNM news


Dr. Purnanand Duddu Sarma
Healthcare
Biotechnology
NASDAQ Capital Market

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.